CHU Lyon Sud

The trials here

What the 15 trials at this site are about, from their registry records.

Conditions

• Diffuse large B-cell lymphoma4 trials
• Mantle cell lymphoma4 trials
• Acute myeloid leukaemia2 trials
• Atopic dermatitis (eczema)1 trial
• Crohn's disease1 trial
• Endometriosis1 trial
• Follicular lymphoma1 trial
• Gastric and oesophageal cancer1 trial
• Multiple myeloma1 trial
• Prostate cancer1 trial

Phase

• Phase 26 trials
• Phase 35 trials

Status

• Completed5 trials
• Recruiting5 trials
• Active, not recruiting4 trials
• Not yet recruiting1 trial

Lead sponsor

• The Lymphoma Academic Research Organisation6 trials
• Janssen Research & Development, LLC2 trials
• EG Labo1 trial
• Federation Francophone de Cancerologie Digestive1 trial
• Karyopharm Therapeutics Inc1 trial
• and 4 more

Running trials

• Not yet recruiting

  Epcoritamab Plus Lenalidomide in Relapsed/Refractory Large B-cell Lymphoma After Second-Line CAR T-cell Therapy

  NCT07814001· Phase 2· The Lymphoma Academic Research Organisation· Source

  Contact: Pierre Sesques, Docteur

• Recruiting

  A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned

  NCT07665450· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

  NCT06852222· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Evaluation of the Acceptability and Therapeutic Maintenance After Substitution of Ustekinumab With a Biosimilar

  NCT07077681· EG Labo· Source

  Contact: Stéphane NANCEY, MD

• Active, not recruiting

  Impact of Ziwig Endotest® on the Management of Patients With Clinical Symptoms of Endometriosis Inconsistent With Their Imaging Work-up

  NCT06794424· ZIWIG· Source

• Recruiting

  Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma

  NCT06558604· Phase 2· The Lymphoma Academic Research Organisation· Source

  Contact: Violaine SAFAR, MD

• Recruiting

  A Study to Learn About Abrocitinib in Adult Patients With Moderate to Severe Atopic Dermatitis.

  NCT05689151· Pfizer· Source

• Active, not recruiting

  Prostate-cancer Treatment Using Stereotactic Radiotherapy for Oligometastases Ablation in Hormone-sensitive Patients

  NCT04115007· Phase 3· UNICANCER· Source

• Active, not recruiting

  A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy

  NCT04023526· Phase 2· OncoVerity, Inc.· Source

• Active, not recruiting

  Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

  NCT02227251· Phase 2· Karyopharm Therapeutics Inc· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Acute myeloid leukaemia1 recruiting
• Atopic dermatitis (eczema)1 recruiting
• Crohn's disease1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Follicular lymphoma1 recruiting
• Mantle cell lymphoma1 recruiting
• Multiple myeloma1 recruiting

Closed trials

• Completed

  FERtility After Therapy With Intensive Lymphoma in Young Women: LNH-03 1B, LNH-03 2B, LNH-07 3B, GAINED Follow-up

  NCT06592846· The Lymphoma Academic Research Organisation· Source

• Completed

  Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy

  NCT04703686· Phase 2· The Lymphoma Academic Research Organisation· Source

• Completed

  PHASE III RANDOMISED TRIAL to EVALUATE FOLFOX with or WITHOUT DOCETAXEL (TFOX) AS 1st LINE CHEMOTHERAPY for LOCALLY ADVANCED or METASTATIC OESOPHAGO-GASTRIC CARCINOMA

  NCT03006432· Phase 3· Federation Francophone de Cancerologie Digestive· Source

• Completed

  Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven Maintenance

  NCT02896582· Phase 2· The Lymphoma Academic Research Organisation· Source

• Completed

  R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL

  NCT01865110· Phase 3· The Lymphoma Academic Research Organisation· Source